Adherence to Therapeutic Recommendations in Patients Suffering from Multiple Sclerosis
DOI:
https://doi.org/10.15225/PNN.2020.9.3.3Keywords
adherence, multiple sclerosis, therapeutic recommendationsAbstract
Introduction. Multiple sclerosis is a chronic, inflammatory, immune demyelinating disease of the central nervous system. The effectiveness of MS treatment depends primarily on the effectiveness of drugs and the patient’s compliance with the principles of therapy.
Aim. The main aim of the study was to assess the level of adherence to therapeutic recommendations in patients with multiple sclerosis.
Material and Methods. The research was carried out at the Department of Neurology and Clinical Neuroimmunology of the Regional Specialist Hospital in Grudziądz. On average 165 patients suffering from multiple sclerosis were qualified for the study. The study was conducted using the method of diagnostic survey. The variables were measured using the proprietary questionnaire containing sociodemographic and medical data and the standardized adherence scale in chronic diseases (ACDS).
Results. The analysis of own research showed that patients with high-level multiple sclerosis adhere to the therapeutic recommendations (p = 0.001). The study group reported the fatigue syndrome at all ACDS levels (p = 0.002). There was no relationship between the occurrence of adverse effects of pharmacotherapy and the level of compliance with therapeutic recommendations (p > 0.05).
Conclusions. It was found that the level of adherence to therapeutic recommendations in patients suffering from multiple sclerosis in the study group remained at a high level. (JNNN 2020;9(3):103–107)
References
Haynes R.B., McDonald H.P., Garg A.X. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288(22):2880–2883.
Evans C., Marrie R.A., Zhu F. et al. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. Pharmacoepidemiol Drug Saf. 2017;26(6):702–711.
O’Rourke K.E.T., Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler. 2005;11(1):46–50.
Treadaway K., Cutter G., Salter A. et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256(4):568–576.
Kołtuniuk A., Rosińczuk J. Adherence to disease-modifying therapies in patients with multiple sclerosis. Patient Prefer Adherence. 2018;12:1557–1566.
Kubica A., Kosobucka A., Michalski P. i wsp. Skala adherence w chorobach przewlekłych — nowe narzędzie do badania realizacji planu terapeutycznego. Folia Cardiol. 2017;12(1):19–26.
SM — walcz o siebie. Raport z badania ilościowego. 2015 rok. Retrieved June 19, 2020, from http://www.sm-walczosiebie.pl/badania/
Devonshire V., Lapierre Y., Macdonell R. et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69–77.
Giovannoni G., Southam E., Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler. 2012;18(7):932–946.
Menzin J., Caon C., Nichols C., White L.A., Friedman M., Pill M.W. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19(1 Suppl A):S24–40.
Benedict R.H., Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011;7(6):332–342.
Higginson C.I., Wheelock V.L., Levine D., King D.S., Pappas C.T., Sigvardt K.A. Cognitive deficits in essential tremor consistent with frontosubcortical dysfunction. J Clin Exp Neuropsychol. 2008;30(7):760–765.
Rao S.M., Leo G.J., Ellington L., Nauertz T., Bernardin L., Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991;41(5):692–696.
Arroyo E., Grau C., Ramo C., Parra J., Sánchez-Soliño O., por el grupo espanol del estudio GAP. Global adherence project to disease–modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results. Neurologia. 2010;25(7):435–442.
Di Battista G., Bertolotto A., Gasperini C., Ghezzi A., Maimone D., Solaro C. Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy’s Adherence, Hospital Reliability’s Perception, and Services Provided Quality. Mult Scler Int. 2014;2014:752318.
Costello K., Kennedy P., Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10(9):225.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 411
Number of citations: 0